Dyax Has Returned 22.0% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Tue May 13, 10:10AM CDT
SmarTrend identified a Downtrend for Dyax (NASDAQ
Dyax Shares Down 23.7% Since SmarTrend's Sell Call (DYAX)
Comtex SmarTrend(R) - Tue May 06, 9:22AM CDT
SmarTrend identified a Downtrend for Dyax (NASDAQ
Dyax Corp. (DYAX) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:36AM CDT
Dyax Corp. (DYAX) Sees Hammer Chart Pattern: Time to Buy?
Dyax Corp. to Participate in the Deutsche Bank 39th Annual Health Care Conference
Business Wire - Thu May 01, 7:00AM CDT
Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Deutsche Bank 39th Annual Health Care Conference being held May 7-8, 2014 at the InterContinental Hotel in Boston, MA. George Migausky, Chief Financial Officer of Dyax, will present on Wednesday, May 7 at 11:20 AM (ET). Mr. Migausky will provide a corporate update on the Company's key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the LFRP.
Dyax's net loss narrows to USD5.7m in Q1 2014
M2 - Thu May 01, 6:05AM CDT
Biopharmaceutical company Dyax (NasdaqGM
Forthcoming Earnings Releases -- Research on Fidelity National Financial, Chemtura, Dyax, and JDS Uniphase
PR Newswire - Thu May 01, 3:12AM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: Fidelity National Financial Inc. (NYSE: FNF), Chemtura Corp. (NYSE: CHMT), Dyax Corp. (NASDAQ: DYAX) and JDS Uniphase Corp. (NASDAQ: JDSU). Full earnings notes on FNF, CHMT, DYAX and JDSU can be downloaded upon signing up at:
Dyax Corp. Announces First Quarter 2014 Financial Results
Business Wire - Wed Apr 30, 3:02PM CDT
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the first quarter ended March 31, 2014. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers - the hereditary angioedema (HAE) business, including KALBITOR(R) (ecallantide) and DX-2930, and the Licensing and Funded Research Portfolio (LFRP).
Top Gainers Pre-Market Notes -- Research on JinkoSolar Holding, Pacific Ethanol, Ruckus Wireless, and Dyax
PR Newswire - Wed Apr 23, 10:30AM CDT
The trading session on Tuesday, April 22, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,514.37, up 0.40% and the NASDAQ Composite closed at 4,161.46, up 0.97%. The S&P 500 finished the session 0.41% higher at 1,879.55. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including JinkoSolar Holding Co. Ltd (NYSE: JKS), Pacific Ethanol Inc. (NASDAQ: PEIX), Ruckus Wireless Inc. (NYSE: RKUS) and Dyax Corp. (NASDAQ: DYAX). Free technical research on JKS, PEIX, RKUS and DYAX can be downloaded upon signing up at:
Dyax Corp. to Host First Quarter 2014 Earnings Call and Webcast
Business Wire - Thu Apr 17, 7:00AM CDT
Dyax Corp. (NASDAQ
Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
Business Wire - Wed Apr 16, 7:01AM CDT
Dyax Corp. (NASDAQ: DYAX) announced today the appointment of Todd Bazemore as Executive Vice President and Chief Commercial Officer. Mr. Bazemore will be responsible for leading Dyax's commercial organization which currently markets KALBITOR(R) (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older.
The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
at The Street - Tue Apr 15, 11:23AM CDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.
Downtrend Call Working As Dyax Stock Falls 15.0% (DYAX)
Comtex SmarTrend(R) - Mon Apr 14, 9:18AM CDT
SmarTrend identified a Downtrend for Dyax (NASDAQ
Dyax wins FDA approval to include use of KALBITOR for treating HAE acute attacks in patients 12 years of age and older
M2 - Fri Apr 04, 6:08AM CDT
Biopharmaceutical company Dyax (NasdaqGM
Dyax Receives FDA Approval to Expand Use of KALBITOR(R) (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema to Patients 12 Years of Age and Older
Business Wire - Thu Apr 03, 3:05PM CDT
Dyax Corp. (NASDAQ
Dyax Corp. (DYAX) in Focus: Stock Up 6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:44AM CDT
Dyax Corp. was a big mover last session, as the company saw its shares rally nearly 6% on the day.
Dyax Corporation (DYAX) Marked As A Dead Cat Bounce Stock
at The Street - Thu Mar 27, 9:07AM CDT
Trade-Ideas LLC identified Dyax Corporation (DYAX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Dyax reports full exercise of 1.2m additional shares in underwriters' option
M2 - Wed Mar 26, 3:01AM CDT
Biopharmaceutical company Dyax (NasdaqGM
Dyax Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Tue Mar 25, 3:05PM CDT
Dyax Corp. (NASDAQ: DYAX) today announced that the underwriters of its previously announced public offering have exercised in full their option to purchase an additional 1,200,000 shares of Dyax's common stock at a price to the public of $9.25 per share, less customary underwriting discounts and commissions. The net proceeds of approximately $10.4 million from the exercise of the option brings the aggregate net proceeds from the offering to approximately $80.0 million, after deducting the underwriting discount and other estimated offering expenses payable by Dyax. The additional shares were delivered to the underwriters on March 25, 2014.